2023
Krebs von den Lungen 6 (KL-6) is a novel diagnostic and prognostic biomarker in pleural mesothelioma
Stockhammer P, Baumeister H, Ploenes T, Bonella F, Theegarten D, Dome B, Pirker C, Berger W, Hegedüs L, Baranyi M, Schuler M, Deshayes S, Bölükbas S, Aigner C, Blanquart C, Hegedüs B. Krebs von den Lungen 6 (KL-6) is a novel diagnostic and prognostic biomarker in pleural mesothelioma. Lung Cancer 2023, 185: 107360. PMID: 37713954, DOI: 10.1016/j.lungcan.2023.107360.Peer-Reviewed Original ResearchKrebs von den Lungen-6KL-6 levelsPleural mesotheliomaIndependent validation cohortPM patientsPrognostic biomarkerLungen-6Overall survivalValidation cohortPrimary cell linesHigher KL-6 levelsLower KL-6 levelsChemiluminescence enzyme immunoassayPleural effusion levelsSystemic treatment optionsBetter overall survivalNon-malignant controlsPleural effusion samplesCell line supernatantsMucin-1 glycoproteinCell linesMUC1 mRNA expressionEffusion levelsPleural disordersConsecutive patients
2019
1849P Pleural effusion TGF-beta is highly diagnostic and prognostic in malignant pleural mesothelioma
Stockhammer P, Ploenes T, Schuler M, Langer S, Aigner C, Hegedus B. 1849P Pleural effusion TGF-beta is highly diagnostic and prognostic in malignant pleural mesothelioma. Annals Of Oncology 2019, 30: v750-v751. DOI: 10.1093/annonc/mdz266.008.Peer-Reviewed Original ResearchMalignant pleural mesotheliomaNon-malignant pleural diseaseTGF-β levelsMPM patientsPleural mesotheliomaNon-epithelioid malignant pleural mesotheliomaMultivariate Cox regression modelWorse overall survivalCox regression modelFuture clinical trialsPleural effusion samplesAdvanced diseaseMultimodality treatmentOverall survivalDismal prognosisEpithelioid tumorsPleural effusionPleural diseaseAggressive malignancyClinical trialsPrognostic biomarkerPatientsReliable biomarkersEffusion samplesSignificant negative correlation
2017
Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma
Klikovits T, Stockhammer P, Laszlo V, Dong Y, Hoda MA, Ghanim B, Opitz I, Frauenfelder T, Nguyen-Kim TDL, Weder W, Berger W, Grusch M, Aigner C, Klepetko W, Dome B, Renyi-Vamos F, Oehler R, Hegedus B. Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma. Scientific Reports 2017, 7: 16456. PMID: 29184132, PMCID: PMC5705645, DOI: 10.1038/s41598-017-16551-7.Peer-Reviewed Original ResearchConceptsMalignant pleural mesotheliomaNon-malignant pleural diseasePlasma C4d levelsC4d levelsHealthy volunteersInduction chemotherapyMPM patientsPleural mesotheliomaTumor volumeMultivariate Cox regression modelEctopic lymphoid structuresBetter overall survivalCox regression modelHigher tumor volumeNew prognostic biomarkerPlasma C4dOverall survivalProgressive diseaseLymphoid structuresPleural diseaseC4d immunohistochemistryPrognostic biomarkerTumor stromaPatientsChemotherapeutic response
2015
160P Pretreatment Serum Albumin Level is an Independent Prognostic Biomarker in Malignant Pleural Mesothelioma
Klikovits T, Stockhammer P, Dong Y, Jakopovic M, Brcic L, Dome B, Hegedus B, Samarzija M, Klepetko W, Hoda M. 160P Pretreatment Serum Albumin Level is an Independent Prognostic Biomarker in Malignant Pleural Mesothelioma. Annals Of Oncology 2015, 26: i48. DOI: 10.1093/annonc/mdv052.06.Peer-Reviewed Original Research